Literature DB >> 28304115

Extracorporeal photopheresis in pediatric patients: Practical and technical considerations.

Robert A DeSimone1, Joseph Schwartz2, Jennifer Schneiderman3.   

Abstract

In adults, extracorporeal photopheresis (ECP) is widely utilized for a variety of indications, most commonly cutaneous T-cell lymphoma, acute or chronic graft-versus-host disease (GVHD), solid organ transplant rejection, and other autoimmune and T-cell-mediated disorders. In pediatric patients, the majority of case series and reports have focused on its use in the management of acute and chronic GVHD. Currently utilized ECP technologies were designed for adult patients and there are several challenges in adapting these technologies for use in children. In our review, we focus on practical considerations and procedural modifications for ECP use in pediatric patients, with special attention to patient safety.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  extracorporeal photopheresis (ECP); graft-versus-host disease (GVHD); pediatrics; therapeutic apheresis

Mesh:

Year:  2017        PMID: 28304115     DOI: 10.1002/jca.21534

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  2 in total

1.  Management of Chronic Graft-vs.-Host Disease in Children and Adolescents With ALL: Present Status and Model for a Personalised Management Plan.

Authors:  Agnieszka Sobkowiak-Sobierajska; Caroline Lindemans; Tomas Sykora; Jacek Wachowiak; Jean-Hugues Dalle; Halvard Bonig; Andrew Gennery; Anita Lawitschka
Journal:  Front Pediatr       Date:  2022-02-18       Impact factor: 3.418

2.  European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 - Part 2.

Authors:  R Knobler; P Arenberger; A Arun; C Assaf; M Bagot; G Berlin; A Bohbot; P Calzavara-Pinton; F Child; A Cho; L E French; A R Gennery; R Gniadecki; H P M Gollnick; E Guenova; P Jaksch; C Jantschitsch; C Klemke; J Ludvigsson; E Papadavid; J Scarisbrick; T Schwarz; R Stadler; P Wolf; J Zic; C Zouboulis; A Zuckermann; H Greinix
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-09-22       Impact factor: 9.228

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.